Plain-English translation of NCT06015022 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a natural compound called , which comes from green tea, can help prevent liver cancer in people who have cirrhosis. The study will give some participants the medication and others a placebo (a dummy pill) for 24 weeks to see if the treatment can safely reduce markers of cancer risk in the blood.
People with cirrhosis have a much higher risk of developing liver cancer, and doctors want to find ways to prevent it from starting in the first place. This medication may help protect the liver, but researchers need to test whether it actually works and is safe for this purpose.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly over 6 months and take a daily capsule containing either the medication or a placebo. Researchers will check your blood to see if the treatment is affecting markers of cancer risk and to watch for any side effects. At the end of week 8, if your blood markers aren't improving, your dose may increase. The study team will also ask about your quality of life and may optionally take a small liver tissue sample to look more closely at how the treatment is working.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Sponsor
University of Texas Southwestern Medical Center
Enrollment target
~60 participants
Started
September 2024
Primary completion
August 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yujin Hoshida, MD, PhD
UT Southwestern
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.